Stockscreener 앱 받기
4.22
1.20%
0.05
시간 외 거래:
4.22
전일 마감가:
$4.17
열려 있는:
$4.19
하루 거래량:
542.17K
Relative Volume:
1.82
시가총액:
$208.69M
수익:
$7.15M
순이익/손실:
$-20.60M
주가수익비율:
8.8917
EPS:
0.4746
순현금흐름:
$-97.99M
1주 성능:
+4.98%
1개월 성능:
-10.21%
6개월 성능:
+83.48%
1년 성능:
+109.95%
1일 변동 폭
$4.18
$4.50
1주일 범위
$4.01
$4.50
52주 변동 폭
$1.57
$5.495
Whitehawk Therapeutics Inc Stock (WHWK) Company Profile
명칭
Whitehawk Therapeutics Inc
전화
551-321-2234
주소
2 HEADQUARTERS PLAZA, MORRISTOWN
Compare WHWK vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
WHWK
Whitehawk Therapeutics Inc
|
4.22 | 202.76M | 7.15M | -20.60M | -97.99M | 0.4746 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Whitehawk Therapeutics Inc Stock (WHWK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-05 | 개시 | Oppenheimer | Outperform |
| 2024-08-27 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-08-21 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-08-21 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2023-12-15 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-01-11 | 개시 | Jefferies | Buy |
| 2021-10-01 | 개시 | Cowen | Outperform |
| 2021-09-14 | 개시 | Ladenburg Thalmann | Buy |
| 2021-09-08 | 개시 | Piper Sandler | Overweight |
모두보기
Whitehawk Therapeutics Inc 주식(WHWK)의 최신 뉴스
Whitehawk Therapeutics shareholders elect directors and approve proposals at annual meeting - Investing.com Nigeria
Whitehawk Shareholders Approve Directors, Pay and Auditor - TipRanks
Shareholders of Whitehawk Therapeutics (NASDAQ: WHWK) approve directors, pay and auditor - Stock Titan
Is Whitehawk Therapeutics (WHWK) One Of The Hot Biotech Stocks Under $5 To Buy? - Insider Monkey
[EFFECT] Whitehawk Therapeutics, Inc. SEC Filing - Stock Titan
WHWK Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift StockMid-Term Outlook - newsline.com
Whitehawk Therapeutics Announces $87.5 Million Private Placement Financing - Global Legal Chronicle
Whitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference - marketscreener.com
Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026 - The AI Journal
Whitehawk Therapeutics (WHWK) Slides 1.26% as Biotech Sentiment Weighs – Key Support Test LoomsBuyback Factor - newsline.com
WHWK: Selling Stockholder Offers 22.32 Million Shares - GuruFocus
Whitehawk Therapeuticsfiles to offer and resell up to 22.32 million shares of common stock by selling stockholders - marketscreener.com
Whitehawk Therapeutics (WHWK) registers 22.3M shares after $87.5M placement - Stock Titan
Whitehawk CEO to speak at Jefferies 2026 healthcare gathering in NYC - Stock Titan
Whitehawk Therapeutics (WHWK) Edges Lower as Stock Hovers Near Key SupportHigh Volume Node - The Legal Advocate
WHWK: Innovative ADC platform shows strong clinical progress and industry validation for oncology targets - TradingView
WHWK News | WHITEHAWK THERAPEUTICS INC (NASDAQ:WHWK) - ChartMill
WHWK Q1 2026 Earnings: EPS Beat Drives Stock Rally Despite No RevenueGuidance Update - newsline.com
WHWK Q1 2026 Earnings: EPS Beat Drives Positive Sentiment Despite Revenue GapGuidance Update - The Legal Advocate
WHWK Stock Edges Up After Hours: Firm Boosts Pipeline Of Cancer Drugs On The Heels Of Capital Raise - Stocktwits
WHWK Q1 2026 Earnings: Narrower-Than-Expected Loss Lifts SharesGeographic Revenue Trends - The Legal Advocate
JonesTrading Maintains Whitehawk Therapeutics(WHWK.US) With Buy Rating, Maintains Target Price $7 - Moomoo
WHWK Q1 2026 Earnings: EPS Beat by 12.1% as Cost Discipline Gains TractionForward Guidance Trends - newsline.com
Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for CPT113 Linker-Payload Technology and Advances Clinical Programs – Minichart - Minichart
Whitehawk expands ADC pipeline with Hangzhou DAC option deal - Investing.com UK
Whitehawk Expands CPT113 ADC Platform Through New Option Deal - TipRanks
Whitehawk Therapeutics expands ADC pipeline with option for CPT113 across up to five programs - TradingView
Whitehawk Therapeutics (WHWK) Climbs +3.69% — Resistance at $4.43 in Focus 2026-05-20Option Breadth - Newser
Cancer treatment developer Whitehawk joins TD Cowen oncology summit - Stock Titan
Whitehawk Therapeutics to Participate in the TD Cowen 7th Annual Oncology Innovation Summit - PR Newswire
Acuta Capital boosts Whitehawk (WHWK) stake to about 9% after PIPE - Stock Titan
Whitehawk Therapeutics (WHWK) CMO receives 19,132-share stock grant at $3.92 - Stock Titan
Whitehawk Therapeutics (WHWK) executive awarded 51,020 shares in Form 4 filing - Stock Titan
Whitehawk Therapeutics (WHWK) CFO receives 38,265-share stock award - Stock Titan
Whitehawk Therapeutics (WHWK) CEO awarded 51,021 shares in new stock grant - Stock Titan
Whitehawk Therapeutics (WHWK) director gains stock grant and large pre-funded warrant - Stock Titan
Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum - marketscreener.com
WHWK PE Ratio & Valuation, Is WHWK Overvalued - Intellectia AI
WHWK SEC FilingsWhitehawk Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Whitehawk Therapeutics, Inc.Common Stock (NQ: WHWK - The Chronicle-Journal
Whitehawk Therapeutics: 'Hold' On Name Change, Next Generation PTK7 ADC Targeting (WHWK) - Seeking Alpha
Avoro boosts Whitehawk Therapeutics (WHWK) stake with pre-funded PIPE warrants - Stock Titan
Avoro Capital Advisors boosts Whitehawk (NASDAQ: WHWK) stake with 6.38M pre-funded warrants - Stock Titan
JonesTrading Initiates Whitehawk Therapeutics(WHWK.US) With Buy Rating, Announces Target Price $7 - Moomoo
May 2026's Promising Penny Stocks - simplywall.st
Wilson Sonsini Advises Whitehawk Therapeutics on $87.5 Million PIPE Financing - Wilson Sonsini
Whitehawk Therapeutics Raises $87.5M in Private Placement to Advance Antibody Drug Conjugate Cancer Pipeline - Minichart
Whitehawk Therapeutics announces $87.5m private placement equity financing - marketscreener.com
Whitehawk Therapeutics raises $87.5m in private placement By Investing.com - Investing.com Australia
Whitehawk Therapeutics Raises $87.5M PIPE Financing to Advance ADC Cancer Pipeline - citybiz
Whitehawk Therapeutics Announces $87.5 Million PIPE Financing - TipRanks
Whitehawk Therapeutics Inc (WHWK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Whitehawk Therapeutics Inc 주식 (WHWK) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Giacobello Scott M. | CHIEF FINANCIAL OFFICER |
Apr 15 '26 |
Sale |
3.86 |
77,000 |
297,220 |
436,824 |
2.60%
0.94%
자본화:
|
볼륨(24시간):